Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol

Indian Heart Journal

Volumn 60, Issue 3, 2008, Pages 215-222

  Harikrishnan, S ^a   Rajeev, E ^a   Tharakan, Jaganmohan A ^a   Titus, Thomas ^a   Ajit Kumar, V K ^a   Sivasankaran, S ^a   Krishnamoorthy, K M ^a   Nair, Krishnakumar ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Atherosclerosis; Coronary artery disease; Dyslipidemia; High density lipoprotein cholesterol; Niacin; Nicotinic acid

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MALE; MONOTHERAPY; MYOPATHY; NOSE CONGESTION; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH PAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NIACIN; PROSPECTIVE STUDIES; PYRROLES; VITAMIN B COMPLEX;

EID: 57349161175     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham Offspring Study. Am J Med 1991;90:11-16.
2. Bruckert E, Hansel B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract 2007 Jul 26; [Epub ahead of print]
3. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatmentand lipid levels with major coronary events: VA-HIT: A randomized controlledtrial. JAMA 2001;285:1585-1591.
4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
5. Kashyap ML, Tavintharan S, Kamanna VS. Optimal therapy of low levels of high density lipoprotein-cholesterol. Am J Cardiovasc Drugs 2003;3:53-65.
6. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid A position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-1268.
7. Birjmohun RS, Hutten BA, Kastelein JJP, Erik SG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005:45:185-197.
8. Goldberg AC. Clinical trial experience with extended-release niacin (niaspan): Dose-escalation study. The American Journal of Cardiology 1998;82(suppl 1):35U-38U.
9. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:419-503.
10. Writing Committee Members. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-572.
11. Shah PK. Emerging HDL-based therapies for atherothrombotic vascular disease. Current Treatment Options in Cardiovascular Medicine 2007;9:60-70.
12. Knopp RH. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am J Cardiol 1998;82(12A):24U-28U.
13. Guyton JR, Goldberg AC, Kreisberg RA. Effectiveness of once-nightly dosing of extended release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-743.
14. Wolfe ML, Vartanian SF. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476-479.
15. Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial. J Cardiovasc Pharmacol Ther 1996;1:107-116.
16. Davignon J, Roederer G, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994;73:339-345.
17. Capuzzi DM, Morgan JM, et al. Beneficial effects of rosuvastatin alone and in combination with extended release Niacin in Patients with a combined hyperlipidemia and low high density lipoprotein levels. Am J Cardiol 2003;91:1304-1310.
18. Van JT, Pan J, Wasty T, et al. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol 2002;89:1306-1308.
19. Gaut ZN, Pocelinko R, Solomon HM, et al. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism 1971;20:1031-1035.
20. Al-Shaer MH. Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? Am Heart J 2005;149:e17.
21. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91:1432-1436.
22. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-437. Epub 2007 Jan 19.
23. Deedwania P, Barter P, Carmena R, et al. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 2006;368:919-928.
24. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-1270.
25. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-1398.
26. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99(suppl):22C-31C.